[HTML][HTML] IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice
Intestinal damage and severe diarrhea are serious side effects of cancer chemotherapy and
constrain the usage of most such therapies. Here we show that interleukin-33 (IL-33)
mediates the severe intestinal mucositis in mice treated with irinotecan (CPT-11), a
commonly used cancer chemotherapeutic agent. Systemic CPT-11 administration led to
severe mucosal damage, diarrhea, and body weight loss concomitant with the induction of IL-
33 in the small intestine (SI). This mucositis was markedly reduced in mice deficient in the IL …
constrain the usage of most such therapies. Here we show that interleukin-33 (IL-33)
mediates the severe intestinal mucositis in mice treated with irinotecan (CPT-11), a
commonly used cancer chemotherapeutic agent. Systemic CPT-11 administration led to
severe mucosal damage, diarrhea, and body weight loss concomitant with the induction of IL-
33 in the small intestine (SI). This mucositis was markedly reduced in mice deficient in the IL …